English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Recombinant plasmid pEGFP-AFP-TK delivered by nano-magnetic fluids targeting killed AFP positive HepG2 cells in vitro].

AIM: To study recombinant plasmid pEGFP-AFP-TK delivered by nano-magnetic fluids targeting killed AFP positive HepG2 cells in vitro.

METHODS: Constructed recombinant plasmid pEGFP-AFP-TK which was delivered by nano-magnetic fluids into AFP positive HepG2 cells and AFP negative SMMC-7721.The fluorescence was detected in order to evaluate the transfection rate, and RT-PCR and Western blot were used to detect the expression of TK gene after transfection. MTT assay was used to evaluate the effect of TK on the proliferation and bystander effect of HepG2 cells in ganciclovir (GCV). Flow cytometry was used to analysis the apoptosis of HepG2 cells.

RESULTS: Nano-magnetic fluids delivered plasmid pEGFP-AFP-TK into HepG2 cells and TK gene was successfully expressed, and the transfection efficacy of nano-magnetic fluids was superior to that of Lipofectamine. RT-PCR and Western blot results demonstrated that TK gene was expressed in HepG2 cells after being transfected with nano-magnetic fluids/pEGFP-AFP-TK. MTT and flow cytometry results showed TK gene exerts cell-killing and bystander effect.

CONCLUSION: Nano-magnetic fluids could successfully deliver pEGFP-AFP-TK into HepG2 cells and induce expression of TK gene, which is promising gene vector for liver cancer gene therapy. AFP enhancer can specifically enhance the expression of target TK gene within the AFP positive cell, and induce bystander effect and apoptosis in the AFP positive HepG2 cell with with GCV.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app